Does the media favor INSM or RYTM?

In the previous week, Rhythm Pharmaceuticals had 11 more articles in the media than Insmed. MarketBeat recorded 17 mentions for Rhythm Pharmaceuticals and 6 mentions for Insmed. Insmed's average media sentiment score of 0.84 beat Rhythm Pharmaceuticals' score of 0.38 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 3 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer RYTM or BNTX?

In the previous week, BioNTech had 12 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 29 mentions for BioNTech and 17 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.38 beat BioNTech's score of 0.14 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 3 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioNTech 12 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer INCY or RYTM?

In the previous week, Rhythm Pharmaceuticals had 8 more articles in the media than Incyte. MarketBeat recorded 17 mentions for Rhythm Pharmaceuticals and 9 mentions for Incyte. Incyte's average media sentiment score of 0.75 beat Rhythm Pharmaceuticals' score of 0.38 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 3 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ROIV or RYTM?

In the previous week, Rhythm Pharmaceuticals had 8 more articles in the media than Roivant Sciences. MarketBeat recorded 17 mentions for Rhythm Pharmaceuticals and 9 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.85 beat Rhythm Pharmaceuticals' score of 0.38 indicating that Roivant Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rhythm Pharmaceuticals 3 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to RYTM or GMAB?

In the previous week, Rhythm Pharmaceuticals had 5 more articles in the media than Genmab A/S. MarketBeat recorded 17 mentions for Rhythm Pharmaceuticals and 12 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.64 beat Rhythm Pharmaceuticals' score of 0.38 indicating that Genmab A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 3 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genmab A/S 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Rhythm Pharmaceuticals (RYTM) Competitors

$97.71 -1.31 (-1.32%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$97.74 +0.03 (+0.03%)

As of 09/18/2026 07:30 PM Eastern

Compare

RYTM vs. INSM, BNTX, INCY, ROIV, and GMAB

Should you buy Rhythm Pharmaceuticals stock or one of its competitors? Rhythm Pharmaceuticals's main competitors and comparable companies include Insmed (INSM), BioNTech (BNTX), Incyte (INCY), Roivant Sciences (ROIV), and Genmab A/S (GMAB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Rhythm Pharmaceuticals compare to Insmed?

Insmed (NASDAQ:INSM) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations and media sentiment.

In the previous week, Rhythm Pharmaceuticals had 11 more articles in the media than Insmed. MarketBeat recorded 17 mentions for Rhythm Pharmaceuticals and 6 mentions for Insmed. Insmed's average media sentiment score of 0.84 beat Rhythm Pharmaceuticals' score of 0.38 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	3 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rhythm Pharmaceuticals has lower revenue, but higher earnings than Insmed. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	43.21	-$1.28B	-$4.11	N/A
Rhythm Pharmaceuticals	$189.76M	35.29	-$196.54M	-$3.11	N/A

Insmed presently has a consensus target price of $204.91, indicating a potential upside of 70.76%. Rhythm Pharmaceuticals has a consensus target price of $140.67, indicating a potential upside of 43.96%. Given Insmed's stronger consensus rating and higher possible upside, equities research analysts clearly believe Insmed is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.76

Insmed has a net margin of -76.94% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Insmed's return on equity of -123.94% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%

Insmed has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.97, meaning that its share price is 97% more volatile than the broader market.

Summary

Insmed beats Rhythm Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Rhythm Pharmaceuticals compare to BioNTech?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and BioNTech (NASDAQ:BNTX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

In the previous week, BioNTech had 12 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 29 mentions for BioNTech and 17 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.38 beat BioNTech's score of 0.14 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	3 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioNTech	12 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Rhythm Pharmaceuticals has a beta of 1.97, indicating that its share price is 97% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market.

Rhythm Pharmaceuticals currently has a consensus target price of $140.67, suggesting a potential upside of 43.96%. BioNTech has a consensus target price of $126.00, suggesting a potential upside of 31.17%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Rhythm Pharmaceuticals is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.76
BioNTech	1 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.68

Rhythm Pharmaceuticals has higher earnings, but lower revenue than BioNTech. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	35.29	-$196.54M	-$3.11	N/A
BioNTech	$3.25B	7.48	-$1.29B	-$7.83	N/A

BioNTech has a net margin of -63.54% compared to Rhythm Pharmaceuticals' net margin of -85.59%. BioNTech's return on equity of -6.86% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%
BioNTech	-63.54%	-6.86%	-6.00%

15.5% of BioNTech shares are held by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are held by company insiders. Comparatively, 19.2% of BioNTech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

BioNTech beats Rhythm Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Rhythm Pharmaceuticals compare to Incyte?

Incyte (NASDAQ:INCY) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

Incyte presently has a consensus target price of $124.05, indicating a potential downside of 1.01%. Rhythm Pharmaceuticals has a consensus target price of $140.67, indicating a potential upside of 43.96%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Rhythm Pharmaceuticals is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	13 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.52
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.76

Incyte has a net margin of 27.71% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Incyte's return on equity of 29.93% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	27.71%	29.93%	22.88%
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%

97.0% of Incyte shares are held by institutional investors. 16.2% of Incyte shares are held by company insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Incyte has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	4.94	$1.29B	$7.85	15.96
Rhythm Pharmaceuticals	$189.76M	35.29	-$196.54M	-$3.11	N/A

Incyte has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.97, indicating that its stock price is 97% more volatile than the broader market.

In the previous week, Rhythm Pharmaceuticals had 8 more articles in the media than Incyte. MarketBeat recorded 17 mentions for Rhythm Pharmaceuticals and 9 mentions for Incyte. Incyte's average media sentiment score of 0.75 beat Rhythm Pharmaceuticals' score of 0.38 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	3 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Incyte beats Rhythm Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Rhythm Pharmaceuticals compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

Roivant Sciences presently has a consensus target price of $45.64, indicating a potential upside of 14.75%. Rhythm Pharmaceuticals has a consensus target price of $140.67, indicating a potential upside of 43.96%. Given Rhythm Pharmaceuticals' higher probable upside, analysts plainly believe Rhythm Pharmaceuticals is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.76

In the previous week, Rhythm Pharmaceuticals had 8 more articles in the media than Roivant Sciences. MarketBeat recorded 17 mentions for Rhythm Pharmaceuticals and 9 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 0.85 beat Rhythm Pharmaceuticals' score of 0.38 indicating that Roivant Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	3 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rhythm Pharmaceuticals has a net margin of -85.59% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%

64.8% of Roivant Sciences shares are owned by institutional investors. 8.8% of Roivant Sciences shares are owned by insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Roivant Sciences has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.97, meaning that its share price is 97% more volatile than the broader market.

Rhythm Pharmaceuticals has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,477.80	-$299.77M	-$0.53	N/A
Rhythm Pharmaceuticals	$189.76M	35.29	-$196.54M	-$3.11	N/A

Summary

Roivant Sciences beats Rhythm Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Rhythm Pharmaceuticals compare to Genmab A/S?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Genmab A/S (NASDAQ:GMAB) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

Rhythm Pharmaceuticals presently has a consensus price target of $140.67, indicating a potential upside of 43.96%. Genmab A/S has a consensus price target of $39.50, indicating a potential upside of 13.70%. Given Rhythm Pharmaceuticals' higher possible upside, equities research analysts plainly believe Rhythm Pharmaceuticals is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	17 Buy rating(s)	0 Strong Buy rating(s)	2.76
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

Genmab A/S has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	35.29	-$196.54M	-$3.11	N/A
Genmab A/S	$3.72B	5.83	$963M	$1.27	27.35

In the previous week, Rhythm Pharmaceuticals had 5 more articles in the media than Genmab A/S. MarketBeat recorded 17 mentions for Rhythm Pharmaceuticals and 12 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.64 beat Rhythm Pharmaceuticals' score of 0.38 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	3 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genmab A/S	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genmab A/S has a net margin of 19.08% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Genmab A/S's return on equity of 14.89% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%
Genmab A/S	19.08%	14.89%	7.73%

Rhythm Pharmaceuticals has a beta of 1.97, meaning that its share price is 97% more volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market.

7.1% of Genmab A/S shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Genmab A/S beats Rhythm Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

Get Rhythm Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RYTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RYTM vs. The Competition

Export

Metric	Rhythm Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.79B	$3.91B	$7.25B	$13.13B
Dividend Yield	N/A	3.65%	2.57%	12.94%
P/E Ratio	-31.42	14.08	273.81	25.39
Price / Sales	35.29	1,407.75	692.78	109.00
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	46.98	15.45	10.45	6.33
Net Income	-$196.54M	-$22.78M	$3.48B	$358.24M
7 Day Performance	-6.69%	-1.22%	0.88%	1.17%
1 Month Performance	-15.57%	-4.44%	-1.59%	-2.59%
1 Year Performance	1.72%	37.78%	18.08%	5.97%

Rhythm Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RYTM Rhythm Pharmaceuticals	2.7797 of 5 stars	$97.71 -1.3%	$140.67 +44.0%	-0.8%	$6.79B	$189.76M	N/A	414	News Coverage Analyst Forecast High Trading Volume
INSM Insmed	3.0533 of 5 stars	$126.29 flat	$205.52 +62.7%	-17.7%	$27.58B	$606.42M	N/A	1,664	Analyst Forecast
BNTX BioNTech	4.3424 of 5 stars	$103.76 flat	$126.00 +21.4%	-0.3%	$26.24B	$3.25B	N/A	7,807	Analyst Forecast Insider Trade
INCY Incyte	3.3476 of 5 stars	$126.75 flat	$124.05 -2.1%	+45.7%	$25.69B	$5.14B	16.15	2,844
ROIV Roivant Sciences	2.8404 of 5 stars	$34.93 flat	$35.14 +0.6%	+163.6%	$25.23B	$8.26M	N/A	860	Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RYTM) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rhythm Pharmaceuticals (RYTM) Competitors

RYTM vs. INSM, BNTX, INCY, ROIV, and GMAB

How does Rhythm Pharmaceuticals compare to Insmed?

Summary

How does Rhythm Pharmaceuticals compare to BioNTech?

Summary

How does Rhythm Pharmaceuticals compare to Incyte?

Summary

How does Rhythm Pharmaceuticals compare to Roivant Sciences?

Summary

How does Rhythm Pharmaceuticals compare to Genmab A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RYTM vs. The Competition

Rhythm Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rhythm Pharmaceuticals (RYTM) Competitors

RYTM vs. INSM, BNTX, INCY, ROIV, and GMAB

How does Rhythm Pharmaceuticals compare to Insmed?

Does the media favor INSM or RYTM?

Which has better earnings & valuation, INSM or RYTM?

Do analysts prefer INSM or RYTM?

Is INSM or RYTM more profitable?

Which has more volatility & risk, INSM or RYTM?

Summary

How does Rhythm Pharmaceuticals compare to BioNTech?

Does the media prefer RYTM or BNTX?

Which has more volatility and risk, RYTM or BNTX?

Do analysts rate RYTM or BNTX?

Which has better valuation and earnings, RYTM or BNTX?

Is RYTM or BNTX more profitable?

Do institutionals and insiders have more ownership in RYTM or BNTX?

Summary

How does Rhythm Pharmaceuticals compare to Incyte?

Do analysts rate INCY or RYTM?

Is INCY or RYTM more profitable?

Do insiders & institutionals believe in INCY or RYTM?

Which has preferable valuation and earnings, INCY or RYTM?

Which has more volatility & risk, INCY or RYTM?

Does the media prefer INCY or RYTM?

Summary

How does Rhythm Pharmaceuticals compare to Roivant Sciences?

Do analysts prefer ROIV or RYTM?

Does the media favor ROIV or RYTM?

Is ROIV or RYTM more profitable?

Do institutionals and insiders believe in ROIV or RYTM?

Which has more volatility and risk, ROIV or RYTM?

Which has better valuation and earnings, ROIV or RYTM?

Summary

How does Rhythm Pharmaceuticals compare to Genmab A/S?

Do analysts recommend RYTM or GMAB?

Which has better earnings & valuation, RYTM or GMAB?

Does the media refer more to RYTM or GMAB?

Is RYTM or GMAB more profitable?

Which has more risk & volatility, RYTM or GMAB?

Do insiders & institutionals believe in RYTM or GMAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RYTM vs. The Competition

Rhythm Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools